The concept that different TP53 germline alterations confer a preferential association with a tumor phenotype is supported by the evidence that carriers of the founder mutation TP53 p.R337H in southern Brazil exhibit mainly adrenocortical tumors (ACT) in children, although ACTs are rare cancers [66]. This evidence concerns the gene TP53 and adrenal cortex neoplasm.